In the last trading session, 9.24 million shares of the Pacific Biosciences of California Inc (NASDAQ:PACB) were traded, and its beta was 2.05. Most recently the company’s share price was $2.06, and it changed around $0.22 or 11.96% from the last close, which brings the market valuation of the company to $561.41M. PACB currently trades at a discount to its 52-week high of $10.65, offering almost -416.99% off that amount. The share price’s 52-week low was $1.16, which indicates that the current value has risen by an impressive 43.69% since then. We note from Pacific Biosciences of California Inc’s average daily trading volume that its 10-day average is 5.89 million shares, with the 3-month average coming to 8.05 million.
Pacific Biosciences of California Inc stock received a consensus recommendation rating of Hold, based on a mean score of 2.20. If we narrow it down even further, the data shows that 0 out of 6 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 4 recommended PACB as a Hold, whereas 0 deemed it a Buy, and 0 rated it as Underweight.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Pacific Biosciences of California Inc (NASDAQ:PACB) trade information
Instantly PACB has showed a green trend with a performance of 11.96% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 2.0800 on recent trading dayincreased the stock’s daily price by 0.96%. The company’s shares are currently down -79.00% year-to-date, but still up 14.44% over the last five days. On the other hand, Pacific Biosciences of California Inc (NASDAQ:PACB) is 21.18% up in the 30-day period. We can see from the shorts that 48.54 million shares have been sold at a short interest cover period of 5.67 day(s).
The consensus price target as assigned by Wall Street analysts is $3, which translates to bulls needing to increase their stock price by 31.33% from its current value. Analyst projections state that PACB is forecast to be at a low of $2 and a high of $4.
Pacific Biosciences of California Inc (PACB) estimates and forecasts
Pacific Biosciences of California Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 24.85 percent over the past six months and at a 14.41% annual growth rate that is well below the industry average of 14.60%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -9.76%. Pacific Biosciences of California Inc earnings are expected to increase by 7.73% in 2024, but the outlook is negative -1.00% per year for the next five years.
PACB Dividends
Pacific Biosciences of California Inc’s next quarterly earnings report is expected to be released in November.
Pacific Biosciences of California Inc (NASDAQ:PACB)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 1.87% of Pacific Biosciences of California Inc shares, and 86.76% of them are in the hands of institutional investors. The stock currently has a share float of 88.41%. Pacific Biosciences of California Inc stock is held by 318.0 institutions, with ARK INVESTMENT MANAGEMENT LLC being the largest institutional investor. By 2024-06-30, it held 12.3202% of the shares, which is about 33.21 million shares worth $45.5 million.
VANGUARD GROUP INC, with 9.6443% or 26.0 million shares worth $35.62 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
